Brief: Basilea Receives USD 6 Mln From Barda For Antibiotic Ceftibuten-Ledaborbactam Development

Basilea Pharmaceutica AG, Allschwil

25/02/2026 06:19

Feb 25 (Reuters) - Basilea Pharmaceutica AG Allschwil BSLN.S:

REG-BASILEA RECEIVES FURTHER USD 6 MILLION FROM BARDA TO CONTINUE DEVELOPMENT OF NOVEL ANTIBIOTIC CEFTIBUTEN-LEDABORBACTAM

BASILEA PHARMACEUTICA -  COULD PROVIDE UP TO USD 147 MILLION OF ADDITIONAL NON-DILUTIVE FUNDING

Source text: ID:nGNE3zRsmt

Further company coverage: BSLN.S

 (Gdansk Newsroom)

 (((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600);))